Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin

Lonza will manufacture talactoferrin at its microbial facility in Kouřim, Czech Republic

12-Apr-2012 - Lonza and Agennix AG announced an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC). Under the agreement, Lonza will produce commercial ...

GPC Biotech Merger into new Agennix AG on track to close before the end of 2009

12-Oct-2009 - GPC Biotech AG reported that its planned merger, under which the Company will combine its business with Agennix Incorporated remains on track to close before the end of 2009. The Company resulting from the merger will be called Agennix AG. The Company also reported a change to the future ...

GPC Biotech Shareholders Approve Merger into New Agennix AG

24-Jun-2009 - GPC Biotech AG announced that the shareholders' meeting approved the adoption of the merger agreement between the Company and diagennix GmbH (to be renamed Agennix AG and converted into a stock corporation). Pursuant to the merger agreement, GPC Biotech, as transferring entity, is to be merged ...

GPC Biotech and Agennix Announce Proposed Merger

Pipeline to include novel oncology therapy, talactoferrin, which recently entered Phase 3 clinical testing

20-Feb-2009 - GPC Biotech AG and Agennix, Incorporated announced that the two oncology-focused biotechnology companies have signed a Business Combination Agreement under which they propose to merge their businesses. In the transaction, GPC Biotech is to be merged onto a new German company, which will hold ...